Skip to main content
Premium Trial:

Request an Annual Quote

Lipomics to Use Agilent Tools to Develop Assays for Metabolic Diseases

NEW YORK (GenomeWeb News) — Lipomics Technologies will use certain Agilent Technologies products under a research and diagnostic assay-development agreement, Lipomics said today.
 
Lipomics said it plans to develop biomarker-based assays focused on metabolic diseases caused by problems with lipid regulation.
 
Terms of the deal call for Agilent to contribute its 2100 Bioanalyzer and other products, including liquid and gas chromatographers, microarrays, and software as they are required, Lipomics said.
 
Lipomics said it measures more than 1,500 metabolites to generate profiles of lipid metabolism throughout the body.
 
Michael McNulty, general manager of Agilent’s diagnostics, life sciences, and chemical analysis business, said “both companies see significant synergies in combining” Lipomics’ experience with lipids and disease with Agilent’s “capabilities to separate, detect and analyze molecules. … ”
 
Financial terms of the agreement were not released.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.